10 minutes ago
Pfizer’s 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low
Sales for Pfizer’s COVID-19 vaccine and oral treatment declined nearly 70% annually during the first quarter, underscoring the company’s earnings headaches as heads turned toward weight loss drugs.